The world’s sixth leading cause of cancer kills one American every hour of every day, according to the National Institute of Health.
A new oral cancer screening tool with more than 10 years of research behind it aims to lower that mortality rate.
According to an article in DentistryIQ.com, PeriRx LLC’s launch of SaliMark OSCC, a test that uses the DNA in saliva to test suspicious lesions or oral mucosal abnormality, is available online from the nation’s largest privately owned dental distributor, Benco Dental, among other sources.
According to the DentistryIQ.com story:
The test is indicated for use when a visual oral examination (via naked eye or fluorescent device) detects a suspicious lesion or oral mucosal abnormality. SaliMark OSCC’s highly-accurate risk assessment capabilities can help the clinician make a more informed and confident decision on whether to refer the patient to a specialist for a biopsy.
“Although biopsies are the gold standard for determining pathology, they are invasive procedures that come back negative 90% of the time,” explained PeriRx founder Stephen Swanick. “SaliMark will greatly improve the efficiency and accuracy of any oral cancer exam protocol.”
Based on a discovery by Dr. David Wong of the University of California at Los Angeles and supported with 10 of additional years of research at National Institute of Dental and Craniofacial Research and National Institute of Health, SaliMark OSCC’s regulatory approval process is in progress.
PeriRx, LLC was founded in 2008 in Broomall, Pa., by CEO Stephen M. Swanick. The executive team includes Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.
Learn more at: www.PeriRx.com